astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Антинеопластични средства - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - Други дерматологични препарати - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.